Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study
© Zhang et al.; licensee BioMed Central Ltd. 2014
Received: 12 November 2013
Accepted: 18 July 2014
Published: 26 July 2014
A combination of psychosocial interventions and medications has been highly recommended as a successful treatment package for schizophrenia. Its cost-effectiveness has not been fully explored yet. The aim of the present analysis was to evaluate the cost-effectiveness of antipsychotics combined with psychosocial treatment and treatment as usual for patients with early-stage schizophrenia.
Patients with schizophrenia (N = 1, 268) were assigned to the combination of medication and psychosocial intervention or treatment as usual for up to 12 months. Cost analysis included direct medical costs, direct nonmedical costs and indirect costs. Quality-adjusted life year (QALY) ratings were assessed with Short- Form 6D.
Average monthly psychosocial intervention costs for combined treatment were higher than treatment as usual (p = 0.005), but no significant differences were found in direct costs, indirect costs, and total costs between two groups (all p-values ≥ 0.556). Combined treatment was associated with significant higher QALY ratings than treatment as usual (p = 0.039). Compared with treatment as usual, combined treatment resulted in a gain of 0.031 QALY ratings at an additional cost of US$ 56.4, yielding an incremental cost-effectiveness ratio of US$ 1819.4 per QALY gained.
Despite some limitations, our results supported that medication combined with psychosocial treatment was more cost-effective than treatment as usual for patients with early-stage schizophrenia.
clinicaltrials.gov Identifier: NCT00654576
KeywordsSchizophrenia Cost-effectiveness Psychosocial intervention
Schizophrenia is a severe and chronic illness as well as one of the most expensive illnesses to treat ,, which has a significant impact on individuals, families and societies in terms of both health and economic loss. Schizophrenia is also among the 15 leading causes of disability and the top 10 leading causes of years lost due to disability . In China, there are about 10 million patients suffering from schizophrenia, and it is estimated that the annual economic cost of schizophrenia exceeds 1 billion RMB ,.
Although antipsychotic medications are the mainstay of the treatment for schizophrenia, patients with schizophrenia benefit more from the combined use of antipsychotic drugs and psychosocial treatment than pharmacotherapy alone in delaying or preventing relapse or reducing hospital days ,. Symptomatic relapse or readmission in schizophrenia is both distressing and costly. It can devastate the lives not only of patients, but also of their families .
Most economic evidence in this area focuses on the cost-effectiveness of medications and different ways of organizing mental health care –, and there is still little economic evidence on psychosocial intervention ,. In a previous article, we reported a 1-year randomized clinical trial that examined the effect of medication combined with psychosocial intervention vs medication treatment alone on outcomes of patients with early stage schizophrenia .
The current article presents resulted on measures of health care costs and health related quality of life. The primary outcomes were total health costs and quality-adjusted life year (QALY) ratings. Based on a randomized controlled trial, the present study sought to examine whether medication combined psychosocial intervention represents a more cost-effective intervention than treatment as usual for patients with early stage schizophrenia.
The trial was a multicenter, randomized, and controlled study conducted between January 2005 and October 2007 at 10 clinical sites in China. The background, rationale, and methods of the Early-stage Schizophrenia Outcome Study (ESOS) have been presented in detail previously . This study was approved by the institutional review board at the Second Xiangya Hospital, Chongqing Mental Health Center, Psychiatric Hospital of Jiangxi Province, West China Hospital, Mental Hospital of Henan Province, Beijing Anding Hospital, Shanghai Mental Health Center, Guangzhou Brain Hospital, Hunan Brain Hospital, and Nanjing Brain Hospital. Written informed consent was obtained from the patients or their legal guardians. Additional files 1 and 2 comprise the the full trial protocol and consort statement extension for cluster randomized controlled trials respectively.
Participants were randomly assigned to receive the combination of medication and psychosocial treatment or treatment as usual (medication treatment and brief intervention) and were monitored for up to 12 months or until medication treatment was discontinued for any reason after baseline assessment. Group assignment was based on a 1:1 randomization scheme balanced by sites and medication prescribed by independent investigator according to a computer generated randomization list.
Study participants were enrolled from outpatient psychiatric clinics and under maintenance treatment. Inclusion criteria in this study were: (1) age 18 to 50 years old; (2) met DSM-IV diagnostic criteria for schizophrenia or schizophreniform disorder, as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders–Clinician Version administered by study investigators; (3) length of illness ≤ 5 years; (4) stable clinical condition (Positive and Negative Syndrome Scale PANSS,  total scores ≤60); (5) treated with one of the following 7 oral antipsychotics: chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine or aripiprazole. Patients were excluded if they were: (1) prescribed two or more antipsychotics or long-acting injectable antipsychotics; (2) participating in other therapy programs; (3) pregnant or breastfeeding; or (4) having serious and unstable medical condition.
All patients continued taking the original antipsychotic during the 12-month follow-up period. If a patient’s medication was stopped or switched, patients were classified as discontinued and terminated from the study.
The psychosocial intervention was reported in detail elsewhere . In brief, patients who were assigned to the combined treatment group received medication treatment and were enrolled in a psychosocial intervention program. The psychosocial intervention included 4 evidence-based practices: psychoeducation, family intervention, skills training, and cognitive behavior therapy was conducted monthly for 12 months. Participants received the 4 interventions on the same day, for a total of 48 one-hour sessions. A lunch break and 2 half-hour breaks were provided to maintain engagement and attention. Therapists who had at least 2 years of clinical experience after earning an MD or PhD or at least 5 years of experience after earning a masters degree in clinical psychology delivered the psychosocial intervention.
The brief intervention included case management with antipsychotic medication and supportive interventions, which were provided monthly for 12 months.
Measuring service use and costs
Costs estimates included direct medical costs, direct nonmedical costs, and indirect nonmedical costs. Direct medical costs consisted of intervention costs such as medication tests, therapy and so on, and uptake of health care services, including costs of medication. Service use was documented through a questionnaire completed by the caregiver at the end of every month during the study. Costs were calculated in US dollar ($) for the reference year 2005 in China.
The costs of psychosocial interventions consisted of start-up costs (development and training) and ongoing costs (services, supplies, travel and salary). We assumed that the psychosocial intervention protocol would be prepared by 2 specialists for 120 hours each and a training program would be conducted for 40 clinicians from all 10 psychiatric hospitals. The intervention program would consist of 42-hour sessions by two therapists . We assumed that each session would have 12 participants (6 patients and 6 family carers). The unit cost for each medical procedure was calculated from the price system database built by the National Development and Reform Commission of China . Direct nonmedical costs consisted of costs for traveling and parking. These costs were valued at US $ 0.1 per kilometer and US $ 0.5 per hour parking time.
Indirect nonmedical costs arise when production losses occur due to illness. Production losses can occur under 3 conditions. Patients were absent from paid work due to sick leave (work loss days), or they were ill but continue to work with reduced efficiency (work cutback days), or caregivers were absent from paid work due to take care of patients.
Cost-effectiveness analysis requires a single measure of health related quality of life that reflects both health gains and health losses. Participants were asked to complete Medical Outcome Study Short-Form 36-item questionnaire (SF-36)  at baseline, 6 months, and 12 months. The utility scores of the SF-6D derived from responses to eleven questions on the SF-36 questionnaire are used to calculate the QALYs gained during the follow-up period by weighing the length of time spent in a particular health condition by the utility. The SF-6D has 6 dimensions (physical functioning, role limitations, social functioning, pain, mental health and vitality) which have from 4 to 6 levels of severity . The SF-6D scoring algorithm has been validated and established for the adult Chinese population in Hong Kong in previous studies ,. The general population mean SF-6D preference value is 0.787, which was estimated from the SF-36 data of a general population survey of 2410 adult Chinese in Hong Kong in 1998 .
Other outcomes further assessed treatment effectiveness by measuring rates of treatment discontinuation, symptom severity (PANSS)  and global severity of illness (Clinical Global Impressions Scale) . The social functioning and family burden were rated by the Global Assessment Scale (GAS)  and Family Burden Scale (FBS) , respectively. Agreement among the raters was high for the PANSS, CGI and GAS (Pearson correlation coefficient, 0.78-0.86) at baseline and every 6 months. All raters were kept blind for patient's treatment condition.
All analyses were conducted with the Statistical Package for Social Sciences, version 15.0 (SPSS Inc, Chicago, Illinois). Baseline characteristics were compared between the two groups by analysis of variance, Pearson’s chi-square test, or Fisher’s exact test, as appropriate. Average monthly costs were compared between the groups with use of a mixed model including the same fixed covariates as for the time to discontinuation, plus baseline value, time, the interaction between treatment and time. Time was classified into months (baseline, 3, 6, 9, and 12 months). All statistical tests were two-tailed.
A strategy was considered as cost-effective versus treatment as usual when ICERs were below the cost-utility threshold acceptable in China. We used 3 × the per capita GDP of China in 2005 (US $ 5,100)/QALY as the threshold according to WHO recommendation ,.
In this study, one-way deterministic analysis was carried out to test the model’s robustness. One-way deterministic analysis included modifications of the following inputs: the number of subjects per workshop that was varied from 5 to 3, and the clinical effect and the cost of per workshop that were varied by ± 20%. The psychosocial intervention workshops were designed to be delivered to 6 patients, and the total cost of providing the intervention is the same even if fewer subjects attend. The per-person cost of the intervention therefore varies depending on the number of subjects per workshop. Assuming that the effectiveness of the intervention was the same, we decreased the number of subjects per workshop in sensitivity analysis.
Patient characteristics at the time of random assignment by initial treatment
Combined treatment (n = 580)
Treatment as usual (n = 604)
Marital status No.(%)
Duration of schizophrenia, mo
PANSS total score
CGI severity score
GAS total score
FBS total score
In the intention-to-treat analysis using all available follow-up data, 62.8% of patients completed 1-year evaluation, with significant differences in the proportion of participants in two treatments groups (70.0% for combined treatment group and 56.0% for treatment as usual group, χ 2 = 24.975, df = 1, p < 0.001).
Average monthly costs by treatment group over 12 months
Type of cost (US $)
Combined treatment (n = 580)
Treatment as usual (n = 604)
Direct medical costs
Health care use costsa
Direct nonmedical costs
Comparison of effectiveness by Treatment Groups (adjusted means across all points based on mixed models)
Combined treatment (n = 580)
Treatment as usual (n = 604)
PANSS total scores
Compared with treatment as usual, combined treatment resulted in a gain of 0.031 QALYs at an additional cost of US$ 56.4, yielding an incremental cost-effectiveness ratio of US$ 1819.4 per QALY gained. Considering the common threshold accepted in China (US$ 5,100 per QALY gained), combined treatment could be considered a cost-effective option compared to treatment as usual.
At the end of the study, 14.6 percent of patients in the combined treatment group and 22.5 percent of patients in treatment as usual group had relapsed (χ 2 = 12.899, df = 1, p < 0.001); readmission occurred in 6.5% of patients in the combined treatment group and 11.2% of patients in treatment as usual group (χ 2 = 8.540, df = 1, p = 0.003).
Average CER (US $/QALY)
Base case (BC)
Patients attendance per workshop
5 cases (−16% BC)
4 cases (−33% BC)
3 cases (−50% BC)
Cost per workshop
- 20% BC
- 20% BC
Schizophrenia is a very serious costly mental illness ,. In this relatively large clinical trial of medication combined psychosocial intervention for outpatients with early-stage schizophrenia, we found that combined treatment group had slightly higher QALYs than treatment as usual group, but there were no statistically significant differences in medication costs or total health costs. These results were consistent with previous reports , in which patients were treated with medication and psychosocial intervention substantially increased health gain with lower medical cost. The differences between two groups in FBS total scores and SF-36 PCS and MCS scores in present study further supports previous studies ,,.
These results extend the efficacy and safety outcomes analysis from the first report of the ESOS study, which showed that patients with early-stage schizophrenia receiving combined medication and psychosocial intervention had a lower rate of treatment discontinuation or change, a lower risk of relapse, and improved insight, quality of life, and social functioning compared with those receiving treatment as usual . Average monthly psychosocial intervention costs were higher for combined treatment than treatment as usual, but no significant differences were found in direct costs, indirect costs, and total costs Individual payments play a huge role in the current Chinese health care system. Patients with schizophrenia have to stay at home to take medicine except for hospitalization in mental hospital or seeing doctor in out-patient in China .
Family caregivers experience significant burden in taking care of their patients with schizophrenia, and family members may influence their relative's adherence with medication and other treatment regimens . In our study, the family caregivers of patients assigned to combined treatment reported less burden overall over 12 months than the caregivers of patients assigned to medication only treatment, suggesting that combined treatment may decrease the family burden.
This study has several limitations. First, this was a 12-month trial; a longer-term randomized clinical trial would contribute substantially to understanding cost-effectiveness of psychosocial intervention on schizophrenia. Second, data loss from attrition was considerable. More patients in medication group dropped out for medication discontinuation or relapse than combined treatment group. Partial compliance with antipsychotic medication is associated with an increased risk of inpatient hospitalization. As we all know, relapse and rehospitalization contribute significantly to the economic burden of schizophrenia . However, we did not continue to collect any information when medication discontinuation or clinical relapse happened, also did not measure costs associated with relapse. This may be the important reason why combined psychosocial intervention was substantially more effective (using rates of discontinuation for any cause as the measure of effectiveness), but slightly higher QALYs than medication treatment alone in present study. Third, we used self-report for most of the measures. Self-report can be vulnerable to recall bias. The self-report of medication and care products for example, is often underestimated . Last, this study recruited only patients with early-stage schizophrenia. Further prospective data monitoring studies are needed to evaluate chronic schizophrenic patient costs.
A combination of psychosocial interventions and medications has been highly recommended as a successful treatment package for schizophrenia . Despite there were some limitations, present results confirmed that combined intervention package was more cost-effective than treatment as usual in early stage schizophrenia. Future research is needed to evaluate the longer-term effects on patient outcomes and consider broader measures of health care resource utilization.
We wish to thank all the investigators of Early-stage Schizophrenia Outcome Study (ESOS) who enrolled patients and collected data: Dr. B. Wang, Dr. B. Hu, Dr. X. Sun, Dr. L. Lv, Dr. C. Wang, Dr. Z. Lu, Dr. C. Ma, Dr. T. Guo, and Dr. S. Xie. We are also very grateful to Haijun Deng from School of Public Health, Central South University for assistance in revising our manuscript.
This study was supported by the National Key Technologies R&D Program in the 10th 5-year-plan of China (Grant No. 2004BA720A22); and the National R&D Special Fund for Health Profession (Grant No. 201002003).
- Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005, 66: 1122-1129. 10.4088/JCP.v66n0906.View ArticlePubMedGoogle Scholar
- Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull. 2004, 30: 279-293. 10.1093/oxfordjournals.schbul.a007078.View ArticlePubMedGoogle Scholar
- The Global Burden of Disease: 2004 Update. 2008, WHO, GenevaGoogle Scholar
- Li JF, Lambert CE, Lambert VA: Predictors of family caregivers’ burden and quality of life when providing care for a family member with schizophrenia in the People’s Republic of China. Nurs Health Sci. 2007, 9: 192-198. 10.1111/j.1442-2018.2007.00327.x.View ArticlePubMedGoogle Scholar
- Yang Z, Liu ML: The economic cost of schizophrenia [in Chinese]. Chin Health Econ Mag. 2003, 22: 28-29.Google Scholar
- Patterson TL, Leeuwenkamp OR: Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res. 2008, 100: 108-119. 10.1016/j.schres.2007.12.468.View ArticlePubMedGoogle Scholar
- Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA: Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry. 2005, 162: 2220-2232. 10.1176/appi.ajp.162.12.2220.View ArticlePubMedGoogle Scholar
- Rosenbaum B, Valbak K, Harder S, Knudsen P, Køster A, Lajer M, Lindhardt A, Winther G, Petersen L, Jørgensen P, Nordentoft M, Andreasen AH: The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis. Br J Psychiatry. 2005, 186: 394-399. 10.1192/bjp.186.5.394.View ArticlePubMedGoogle Scholar
- Almond S, Knapp M, Francois C, Toumi M, Brugha T: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004, 184: 346-351. 10.1192/bjp.184.4.346.View ArticlePubMedGoogle Scholar
- Edwards NC, Locklear JC, Rupnow MF, Diamond RJ: Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005, 23 (Suppl 1): 75-89. 10.2165/00019053-200523001-00007.View ArticlePubMedGoogle Scholar
- Barnett PG, Scott JY, Krystal JH, Rosenheck RA: Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2005, 73: 696-702. 10.4088/JCP.11m07070.View ArticleGoogle Scholar
- Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006, 163: 2080-2089. 10.1176/appi.ajp.163.12.2080.View ArticlePubMedGoogle Scholar
- Patel A, Knapp M, Romeo R, Reeder C, Matthiasson P, Everitt B, Wykes T: Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis. Schizophr Res. 2010, 120: 217-224. 10.1016/j.schres.2009.12.003.View ArticlePubMedGoogle Scholar
- Phanthunane P, Vos T, Whiteford H, Bertram M: Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Alloc. 2011, 9: 6-10.1186/1478-7547-9-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Guo XF, Zhai JG, Liu ZN, Fang MS, Wang B, Wang C, Hu B, Sun X, Lv L, Lu Z, Ma C, He X, Guo T, Xie S, Wu R, Xue Z, Chen J, Twamley EW, Jin H, Zhao J: Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry. 2010, 67: 895-904. 10.1001/archgenpsychiatry.2010.105.View ArticlePubMedPubMed CentralGoogle Scholar
- First MB, Spitzer RL, Gibbon M, Williams JBW, Benjamin LS: Structured Clinical Interview for DSM-IV Axis I Disorders–Clinician Version (SCID-CV). 1997, American Psychiatry Press, Washington, DCGoogle Scholar
- Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276. 10.1093/schbul/13.2.261.View ArticlePubMedGoogle Scholar
- Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P: Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009, 12 (Suppl 3): 66-69. 10.1111/j.1524-4733.2009.00630.x.View ArticleGoogle Scholar
- McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, Ruggeri M, Giessler A, Puschner B, Thornicroft G: A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009, 12: 27-31.PubMedGoogle Scholar
- Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002, 21: 271-292. 10.1016/S0167-6296(01)00130-8.View ArticlePubMedGoogle Scholar
- McGhee SM, Brazier J, Lam CLK, Wong LC, Chau J, Cheung A, Ho A: Quality-adjusted life years: population-specific measurement of the quality component. Hong Kong Med J. 2011, 17 (Suppl 6): 17-21.PubMedGoogle Scholar
- Lam CLK, Brazier J, McGhee SM: Valuation of the SF-6D health states is feasible, acceptable, reliable, and valid in a Chinese population. Value Health. 2008, 11: 295-303. 10.1111/j.1524-4733.2007.00233.x.View ArticlePubMedGoogle Scholar
- Lam ETP, Lam CLK, Lo YYC, Grandek B: Psychometrics and population norm of the Chinese (HK) SF-36 Health Survey version 2. HK Pract. 2008, 30: 185-198.Google Scholar
- Guy W: ECDEU Assessment Manual for Psychopharmacology. Rev ed. 1976, Dept of Health, Education, and Welfare, RockvilleGoogle Scholar
- Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976, 33: 766-771. 10.1001/archpsyc.1976.01770060086012.View ArticlePubMedGoogle Scholar
- Pai S, Kapur RL: The burden on the family of a psychiatric patient: development of an interview schedule. Br J Psychiatry. 1981, 138: 332-335. 10.1192/bjp.138.4.332.View ArticlePubMedGoogle Scholar
- Hoch JS, Briggs A, Willan A: Something old, something new, something borrowed, something blue: a framework for the marriage of health economics and cost effectiveness analysis. Health Econ. 2002, 11: 415-430. 10.1002/hec.678.View ArticlePubMedGoogle Scholar
- Chisholm D, Gureje O, Saldivia S, Villalón Calderón M, Wickremasinghe R, Mendis N, Ayuso-Mateos JL, Saxena S: Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ. 2008, 86: 542-551. 10.2471/BLT.07.045377.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhai J, Guo X, Chen M, Zhao J, Su Z: An investigation of economic costs of schizophrenia in two areas of China. Int J Ment Health Syst. 2013, 15: 26-10.1186/1752-4458-7-26.View ArticleGoogle Scholar
- Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA: Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res. 2010, 116: 118-125. 10.1016/j.schres.2009.09.026.View ArticlePubMedGoogle Scholar
- van den Brink M, van den Hout WB, Stiggelbout AM, van de Velde CJ, Kievit J: Cost measurement in economic evaluations of health care: whom to ask?. Med Care. 2004, 42: 740-746. 10.1097/01.mlr.0000132351.78009.a1.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.